metformin has been researched along with Pituitary ACTH Hypersecretion in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To recommend an approach to monitoring and treating hyperglycemia in pasireotide-treated patients with Cushing's disease, a severe clinical condition caused by a pituitary adenoma hypersecreting adrenocorticotropic hormone." | 8.90 | Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. ( Casanueva, FF; Colao, A; De Block, C; Gaztambide, MS; Kumar, S; Seufert, J, 2014) |
| "To recommend an approach to monitoring and treating hyperglycemia in pasireotide-treated patients with Cushing's disease, a severe clinical condition caused by a pituitary adenoma hypersecreting adrenocorticotropic hormone." | 4.90 | Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. ( Casanueva, FF; Colao, A; De Block, C; Gaztambide, MS; Kumar, S; Seufert, J, 2014) |
| "One of the medical treatments used in Cushing's disease is the somatostatin analogue pasireotide, which acts on adrenocorticotropic hormone (ACTH) secretion by the pituitary." | 2.49 | Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide. ( Bertherat, J; Bisot-Locard, S; Borson-Chazot, F; Brue, T; Chanson, P; Cortet-Rudelli, C; Delemer, B; Reznik, Y; Tabarin, A; Vergès, B, 2013) |
| "Metformin was recently suggested to protect from adverse metabolic side-effects of glucocorticoid treatment." | 1.62 | Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study. ( Bidlingmaier, M; Braun, L; Oßwald, A; Reincke, M; Rubinstein, G; Schilbach, K; Schmidmaier, R; Vogel, F; Zopp, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Vogel, F | 1 |
| Braun, L | 1 |
| Rubinstein, G | 1 |
| Zopp, S | 1 |
| Oßwald, A | 1 |
| Schilbach, K | 1 |
| Schmidmaier, R | 1 |
| Bidlingmaier, M | 1 |
| Reincke, M | 1 |
| Colao, A | 1 |
| De Block, C | 1 |
| Gaztambide, MS | 1 |
| Kumar, S | 1 |
| Seufert, J | 1 |
| Casanueva, FF | 1 |
| Reznik, Y | 1 |
| Bertherat, J | 1 |
| Borson-Chazot, F | 1 |
| Brue, T | 1 |
| Chanson, P | 1 |
| Cortet-Rudelli, C | 1 |
| Delemer, B | 1 |
| Tabarin, A | 1 |
| Bisot-Locard, S | 1 |
| Vergès, B | 1 |
2 reviews available for metformin and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide-1 Receptor; Humans; Hypergl | 2014 |
Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
Topics: Biomarkers; Blood Glucose; Clinical Trials as Topic; Drug Therapy, Combination; Glycated Hemoglobin; | 2013 |
1 other study available for metformin and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study.
Topics: Adult; Bone Density; Bone Remodeling; Cohort Studies; Female; Follow-Up Studies; Germany; Glucocorti | 2021 |